Copernicus Receives MilestoneCopernicus Receives Milestone Payment From CFFT To Further Development Of Its Non-Viral Gene Therapy For Cystic Fibrosis Payment From CFFT To Further Development Of Its Non-Viral Gene Therapy For Cystic Fibrosis

Copernicus Therapeutics, Inc. announced that it received a milestone payment from Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT), a non-profit affiliate of the Cystic Fibrosis Foundation. This milestone payment is part of a research, development, and commercialization agreement between CFFT and Copernicus to develop gene therapy to treat cystic fibrosis. Copernicus earned the milestone payment by […]

Cystic Fibrosis Proteins Photographed Interacting

New microscopic pictures show the first-ever physical evidence of interaction between two proteins involved in Cystic Fibrosis (CF) disease. Researchers at the University of Alabama at Birmingham (UAB) studied a CF causing protein and another protein called epithelial sodium channel, or ENaC. Both proteins are known to play a role in CF, but exactly what […]

Drug Discovery Collaboration Announced By Galapagos And Cystic Fibrosis Foundation Therapeutics

Galapagos NV (Euronext & LSE: GLPG) and Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT), the non-profit affiliate of the Cystic Fibrosis Foundation, have announced a new collaboration aimed at discovering new treatments for cystic fibrosis. This new agreement between CFFT and Galapagos’ BioFocus DPI service division is worth up to 5.5 million euros ($8.1 million U.S. […]

PARI’s EFlow Included In Gilead’s NDA Submission For Aztreonam Lysine For Inhalation

PARI Pharma’s eFlow electronic nebulizer was included in Gilead’s (Nasdaq: GILD) recent New Drug Application (NDA) submittal to the U.S. Food and Drug Administration (FDA) for marketing approval of aztreonam lysine for inhalation (75 mg three times daily). Aztreonam lysine for inhalation, delivered by eFlow, is an investigational therapy in development for people with cystic […]

Identifying The Best Candidates For Lung Transplant In Children With Cystic Fibrosis

Lung transplantation, the therapy almost every cystic fibrosis patient (CF) considers at some point to prolong survival, rarely helps children with the disease live longer and, in fact, often increases their risk of dying, University of Utah researchers conclude in the most extensive study of the issue to date. The findings argue strongly for a […]

Pediatric Pulmonary Expert Comments On Study Of Lung Transplants For Cystic Fibrosis

Commenting on a study of lung transplantation for children with cystic fibrosis, a leading pediatric pulmonologist calls the study “startling” in an editorial in this week’s New England Journal of Medicine that accompanies the study. Julian Allen, M.D., who holds the Robert Gerard Morse Endowed Chair in Pediatric Pulmonary Medicine at The Children’s Hospital of […]

Gilead Submits New Drug Application To U.S. FDA For Aztreonam Lysine For Inhalation For Cystic Fibrosis

Gilead Sciences, Inc. (Nasdaq:GILD) announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for marketing approval of aztreonam lysine for inhalation (75 mg three times daily), an investigational therapy in development for people with cystic fibrosis (CF) who have pulmonary Pseudomonas aeruginosa (P. aeruginosa) infection. The NDA […]

New Treatment Guidelines Released By Cystic Fibrosis Foundation

New clinical standards on the treatment of patients with cystic fibrosis (CF) have been released following an exhaustive review of all available literature. The guidelines, a result of a two-year review of original research and systematic review literature from 1983 to 2006, were published in the second issue for November of the American Thoracic Society’s […]

|